For more information, see theDiarrheasection in Gastrointestinal Complications.No data are available on quality of life or treatment after disease progression.
Median time-to-disease progression in the lapatinib-plus-capecitabine arm was 8.4 months compared with 4.4 months in the capecitabine-alone arm (HR, 0.49; 95% CI, 0.34–0.71;P< .001).
There was no difference in OS (HR, 0.92; 95% CI, 0.58–1.46;P= .72).[84][Level of evidence A1] Patients on combination therapy were more likely to develop diarrhea, rash, and dyspepsia.
For more information, see theDiarrheasection in Gastrointestinal Complications.